ADCETRIS (brentuximab vedotin) UK WEBSITE
This website has been developed by Takeda Oncology and contains product and prescribing information intended for UK healthcare professionals. In addition, the site contains specific information for patients prescribed ADCETRIS and general information for the public.
Please select the appropriate option below to continue:
I am a UK Healthcare Professional I have been prescribed ADCETRIS I am a member of the publicReferences
- ADCETRIS Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2859/smpc
Reporting adverse events (UK Healthcare Professionals)
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.
Reporting possible side effects (UK Patients and Public)
ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed on this website or in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.
and ADCETRIS are registered trademarks of Takeda Pharmaceutical Company Limited.
